Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Preferred Stock Liabilities: 2017-2018

Historic Preferred Stock Liabilities for Bicycle Therapeutics (BCYC) over the last 2 years, with Dec 2018 value amounting to $54.6 million.

  • Bicycle Therapeutics' Preferred Stock Liabilities was N/A to $54.6 million in Q4 2018 from the same period last year, while for Dec 2018 it was $54.6 million, marking a year-over-year change of. This contributed to the annual value of $54.6 million for FY2018, which is negligibly% changed negligibly from last year.
  • Per Bicycle Therapeutics' latest filing, its Preferred Stock Liabilities stood at $54.6 million for FY2018, which was down 0.00% from $54.6 million recorded in FY2017.
  • Bicycle Therapeutics' Preferred Stock Liabilities' 5-year high stood at $54.6 million during FY2017, with a 5-year trough of $54.6 million in FY2017.
  • Over the past 2 years, Bicycle Therapeutics' median Preferred Stock Liabilities value was $54.6 million (recorded in 2018), while the average stood at $54.6 million.